The clinical presentation and progression of NAION manifests through: Sudden, painless monocular vision loss occurring over hours to days, often discovered upon awakening Altitudinal visual field defects affecting either the superior or inferior visual field Visual acuity loss ranging from mild (20/30) to severe (counting fingers or worse) Optic disc edema during the acute phase, progressing to optic atrophy over 4-6 weeks Risk of bilateral involvement, with 15% of patients developing NAION in the second eye within five years No effective treatment to restore vision once damage occurs Permanent disability requiring lifestyle adaptations and assistive technologies The pathophysiology of NAION involves impaired perfusion to the anterior portion of the optic nerve head, though the exact mechanism remains incompletely understood
Myth 2: Drinking More Water Enhances Semaglutides Effects Fact: Drinking water is essential for overall health, but there is no scientific evidence to suggest that excessive water intake will enhance the effects of semaglutide
Start your intake Clinical Trial Data: What the Evidence Actually Shows The STEP trials (Semaglutide Treatment Effect in People with Obesity) demonstrated dose-dependent weight loss over 68 weeks
For females, there were more hip fractures with semaglutide (0.3% vs
During follow-up of interventions that induce weight reduction, it has been difficult to determine whether a concurrent reduction of, e.g., visceral fat was in line with the amount of weight lost, or if there was larger reduction than expected
How long has semaglutide been around exactly
